Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 11, 2008

bioMérieux Boosts Molecular Diagnostic Portfolio with Purchase of AviaraDx for $60M

  • bioMérieux acquired AviaraDx for $60 million expanding its portfolio of infectious disease molecular diagnostics to include tests that aid cancer management. The firm also gains AviaraDx’ CLIA-certified lab.

    AviaraDx will operate as an independent legal entity called bioTheranostics. The company has traditionally been focused on R&D with 19 employees and a limited sales team. bioMérieux reports that AviaraDx has had restricted sales and is projected to lose approximately $8 million this year. bioTheranostics is also predicted to have lower sales until 2012 and break even around that year.

    AviaraDx’ diagnostic tests are used to classify cancers on a molecular level to assist with prognosis. The company also has reportedly validated cancer biomarkers and capabilities in gene-expression profiling in tissues.

    Aviara CancerTYPE ID® provides cancer classification, especially for patients diagnosed with metastatic cancer where the origin is uncertain or unknown. Aviara Breast Cancer Index is used to evaluate two Aviara markers (H/I and MGI) for risk prognosis and treatment-response prediction for chemo and hormonal therapy.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »